Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Symmetry breakdown of electron emission in extreme ultraviolet photoionization of argon.
Ilchen M, Hartmann G, Gryzlova EV, Achner A, Allaria E, Beckmann A, Braune M, Buck J, Callegari C, Coffee RN, Cucini R, Danailov M, De Fanis A, Demidovich A, Ferrari E, Finetti P, Glaser L, Knie A, Lindahl AO, Plekan O, Mahne N, Mazza T, Raimondi L, Roussel E, Scholz F, Seltmann J, Shevchuk I, Svetina C, Walter P, Zangrando M, Viefhaus J, Grum-Grzhimailo AN, Meyer M. Ilchen M, et al. Nat Commun. 2018 Nov 7;9(1):4659. doi: 10.1038/s41467-018-07152-7. Nat Commun. 2018. PMID: 30405105 Free PMC article.
Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.
Sagawa ZK, Goman C, Frevol A, Blazevic A, Tennant J, Fisher B, Day T, Jackson S, Lemiale F, Toussaint L, Kalisz I, Jiang J, Ondrejcek L, Mohamath R, Vergara J, Lew A, Beckmann AM, Casper C, Hoft DF, Fox CB. Sagawa ZK, et al. Among authors: beckmann am. Nat Commun. 2023 Mar 6;14(1):1138. doi: 10.1038/s41467-023-36789-2. Nat Commun. 2023. PMID: 36878897 Free PMC article. Clinical Trial.
Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial.
Vanni T, Thomé BC, Sparrow E, Friede M, Fox CB, Beckmann AM, Huynh C, Mondini G, Silveira DH, Viscondi JYK, Braga PE, Silva AD, Salomão MDG, Piorelli RO, Santos JP, Gattás VL, Lucchesi MBB, Oliveira MMM, Koike ME, Kallas EG, Campos LMA, Coelho EB, Siqueira MAM, Garcia CC, Miranda MD, Paiva TM, Timenetsky MDCST, Adami EA, Akamatsu MA, Ho PL, Precioso AR. Vanni T, et al. Among authors: beckmann am. PLoS One. 2022 Oct 18;17(10):e0274943. doi: 10.1371/journal.pone.0274943. eCollection 2022. PLoS One. 2022. PMID: 36256646 Free PMC article. Clinical Trial.
Lyophilization Process Engineering and Thermostability of ID93 + GLA-SE, a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies.
Dutill TS, Archer MC, McCollum J, Press C, McNeill L, Hawkins L, Phan T, Laursen E, Cabullos R, Bouchard L, Castro RJ, Lin MW, Roco J, Blois C, Adeagbo B, Guderian JA, Gerhardt A, Beckmann AM, Trappler EH, Kramer RM, Fox CB. Dutill TS, et al. Among authors: beckmann am. Front Drug Deliv. 2022;2:1043756. doi: 10.3389/fddev.2022.1043756. Epub 2022 Nov 8. Front Drug Deliv. 2022. PMID: 37771324 Free PMC article.
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Day TA, Penn-Nicholson A, Luabeya AKK, Fiore-Gartland A, Du Plessis N, Loxton AG, Vergara J, Rolf TA, Reid TD, Toefy A, Shenje J, Geldenhuys H, Tameris M, Mabwe S, Bilek N, Bekker LG, Diacon A, Walzl G, Ashman J, Frevol A, Sagawa ZK, Lindestam Arlehamn C, Sette A, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-203 study team. Day TA, et al. Lancet Respir Med. 2021 Apr;9(4):373-386. doi: 10.1016/S2213-2600(20)30319-2. Epub 2020 Dec 8. Lancet Respir Med. 2021. PMID: 33306991 Clinical Trial.
The adjuvant GLA-AF enhances human intradermal vaccine responses.
Carter D, van Hoeven N, Baldwin S, Levin Y, Kochba E, Magill A, Charland N, Landry N, Nu K, Frevol A, Ashman J, Sagawa ZK, Beckmann AM, Reed SG. Carter D, et al. Among authors: beckmann am. Sci Adv. 2018 Sep 12;4(9):eaas9930. doi: 10.1126/sciadv.aas9930. eCollection 2018 Sep. Sci Adv. 2018. PMID: 30221194 Free PMC article. Clinical Trial.
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG; TBVPX-113 Study Team. Coler RN, et al. Among authors: beckmann am. NPJ Vaccines. 2018 Sep 4;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018. NPJ Vaccines. 2018. PMID: 30210819 Free PMC article.
58 results